Moffitt Cancer Center is the first healthcare provider in the US to commercially administer a newly-approved therapy for Small Cell Lung Cancer
Moffitt Cancer Center shared on their X/Twitter:
”Moffitt is the first healthcare provider in the US to commercially administer a newly-approved therapy for Small Cell Lung Cancer.
The FDA recently approved Tarlatamab for patients with advanced disease.
View attached video.
Source: Moffitt Cancer Center/X
Moffitt Cancer Center, established in 1986, is a leading institution dedicated to cancer research, treatment, and prevention. With a multidisciplinary approach and state-of-the-art facilities, Moffitt’s commitment to innovative research is reflected in its five multidisciplinary research programs, which integrate teams focused on cancer biology and evolution, chemical biology and molecular medicine, immunology, health outcomes and behavior, and cancer epidemiology. Since receiving its NCI designation in 1998 and NCI-Designated Comprehensive Cancer Center status in 2001, Moffitt Cancer Center continues to lead the charge in advancing cancer care, providing hope and healing to patients worldwide.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023